FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4312057911> ?p ?o ?g. }

• W4312057911 endingPage "2956" @default.
• W4312057911 startingPage "2944" @default.
• W4312057911 abstract "Heterogeneity in progression to Alzheimer's disease (AD) poses challenges for both clinical prognosis and clinical trial implementation. Multiple AD-related subtypes have previously been identified, suggesting differences in receptivity to drug interventions. We identified early differences in preclinical AD biomarkers, assessed patterns for developing preclinical AD across the amyloid-tau-(neurodegeneration) [AT(N)] framework, and considered potential sources of difference by analysing the CSF proteome. Participants (n = 10) enrolled in longitudinal studies at the Knight Alzheimer Disease Research Center completed four or more lumbar punctures. These individuals were cognitively normal at baseline. Cerebrospinal fluid measures of amyloid-β (Aβ)42, phosphorylated tau (pTau181), and neurofilament light chain (NfL) as well as proteomics values were evaluated. Imaging biomarkers, including PET amyloid and tau, and structural MRI, were repeatedly obtained when available. Individuals were staged according to the amyloid-tau-(neurodegeneration) framework. Growth mixture modelling, an unsupervised clustering technique, identified three patterns of biomarker progression as measured by CSF pTau181 and Aβ42. Two groups (AD Biomarker Positive and Intermediate AD Biomarker) showed distinct progression from normal biomarker status to having biomarkers consistent with preclinical AD. A third group (AD Biomarker Negative) did not develop abnormal AD biomarkers over time. Participants grouped by CSF trajectories were re-classified using only proteomic profiles (AUCAD Biomarker Positive versus AD Biomarker Negative = 0.857, AUCAD Biomarker Positive versus Intermediate AD Biomarkers = 0.525, AUCIntermediate AD Biomarkers versus AD Biomarker Negative = 0.952). We highlight heterogeneity in the development of AD biomarkers in cognitively normal individuals. We identified some individuals who became amyloid positive before the age of 50 years. A second group, Intermediate AD Biomarkers, developed elevated CSF ptau181 significantly before becoming amyloid positive. A third group were AD Biomarker Negative over repeated testing. Our results could influence the selection of participants for specific treatments (e.g. amyloid-reducing versus other agents) in clinical trials. CSF proteome analysis highlighted additional non-AT(N) biomarkers for potential therapies, including blood-brain barrier-, vascular-, immune-, and neuroinflammatory-related targets." @default.
• W4312057911 created "2023-01-04" @default.
• W4312057911 creator A5000597778 @default.
• W4312057911 creator A5001703836 @default.
• W4312057911 creator A5012029691 @default.
• W4312057911 creator A5018751073 @default.
• W4312057911 creator A5025837253 @default.
• W4312057911 creator A5035679709 @default.
• W4312057911 creator A5037441723 @default.
• W4312057911 creator A5046330175 @default.
• W4312057911 creator A5063197083 @default.
• W4312057911 creator A5070540397 @default.
• W4312057911 creator A5076073942 @default.
• W4312057911 creator A5077789520 @default.
• W4312057911 creator A5088998527 @default.
• W4312057911 date "2022-12-21" @default.
• W4312057911 modified "2023-10-14" @default.
• W4312057911 title "Proteomic clusters underlie heterogeneity in preclinical Alzheimer’s disease progression" @default.
• W4312057911 cites W1423766661 @default.
• W4312057911 cites W1538814448 @default.
• W4312057911 cites W1912212332 @default.
• W4312057911 cites W1919821049 @default.
• W4312057911 cites W1977541817 @default.
• W4312057911 cites W1986400971 @default.
• W4312057911 cites W2006858320 @default.
• W4312057911 cites W2014897304 @default.
• W4312057911 cites W2026331106 @default.
• W4312057911 cites W2033601413 @default.
• W4312057911 cites W2040647120 @default.
• W4312057911 cites W2041872753 @default.
• W4312057911 cites W2044694582 @default.
• W4312057911 cites W2046582067 @default.
• W4312057911 cites W2049733019 @default.
• W4312057911 cites W2050993765 @default.
• W4312057911 cites W2064415517 @default.
• W4312057911 cites W2066977853 @default.
• W4312057911 cites W2108474398 @default.
• W4312057911 cites W2121236536 @default.
• W4312057911 cites W2124341714 @default.
• W4312057911 cites W2132901471 @default.
• W4312057911 cites W2140652743 @default.
• W4312057911 cites W2141025089 @default.
• W4312057911 cites W2142294527 @default.
• W4312057911 cites W2154067471 @default.
• W4312057911 cites W2161737267 @default.
• W4312057911 cites W2167840686 @default.
• W4312057911 cites W2171808809 @default.
• W4312057911 cites W2316313792 @default.
• W4312057911 cites W2412942072 @default.
• W4312057911 cites W2614881333 @default.
• W4312057911 cites W2738088587 @default.
• W4312057911 cites W2739137023 @default.
• W4312057911 cites W2743373469 @default.
• W4312057911 cites W2770092353 @default.
• W4312057911 cites W2792820766 @default.
• W4312057911 cites W2798054687 @default.
• W4312057911 cites W2803303078 @default.
• W4312057911 cites W2808364202 @default.
• W4312057911 cites W2906702113 @default.
• W4312057911 cites W2922419793 @default.
• W4312057911 cites W2949566851 @default.
• W4312057911 cites W2972040783 @default.
• W4312057911 cites W3026206371 @default.
• W4312057911 cites W3045283356 @default.
• W4312057911 cites W3089555614 @default.
• W4312057911 cites W3095171867 @default.
• W4312057911 cites W3096808785 @default.
• W4312057911 cites W3108547525 @default.
• W4312057911 cites W3114125479 @default.
• W4312057911 cites W3118471420 @default.
• W4312057911 cites W3121411100 @default.
• W4312057911 cites W3134058404 @default.
• W4312057911 cites W3137131062 @default.
• W4312057911 cites W3157398449 @default.
• W4312057911 cites W3181408683 @default.
• W4312057911 cites W3181997110 @default.
• W4312057911 cites W3192559139 @default.
• W4312057911 cites W3205996261 @default.
• W4312057911 cites W3210179375 @default.
• W4312057911 cites W4210987525 @default.
• W4312057911 cites W4295227033 @default.
• W4312057911 doi "https://doi.org/10.1093/brain/awac484" @default.
• W4312057911 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36542469" @default.
• W4312057911 hasPublicationYear "2022" @default.
• W4312057911 type Work @default.
• W4312057911 citedByCount "3" @default.
• W4312057911 countsByYear W43120579112023 @default.
• W4312057911 crossrefType "journal-article" @default.
• W4312057911 hasAuthorship W4312057911A5000597778 @default.
• W4312057911 hasAuthorship W4312057911A5001703836 @default.
• W4312057911 hasAuthorship W4312057911A5012029691 @default.
• W4312057911 hasAuthorship W4312057911A5018751073 @default.
• W4312057911 hasAuthorship W4312057911A5025837253 @default.
• W4312057911 hasAuthorship W4312057911A5035679709 @default.
• W4312057911 hasAuthorship W4312057911A5037441723 @default.
• W4312057911 hasAuthorship W4312057911A5046330175 @default.
• W4312057911 hasAuthorship W4312057911A5063197083 @default.
• W4312057911 hasAuthorship W4312057911A5070540397 @default.

• next